1. Home
  2. CMMB vs DFLI Comparison

CMMB vs DFLI Comparison

Compare CMMB & DFLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMMB
  • DFLI
  • Stock Information
  • Founded
  • CMMB 2004
  • DFLI 2020
  • Country
  • CMMB Israel
  • DFLI United States
  • Employees
  • CMMB N/A
  • DFLI N/A
  • Industry
  • CMMB Biotechnology: Pharmaceutical Preparations
  • DFLI Electronic Components
  • Sector
  • CMMB Health Care
  • DFLI Technology
  • Exchange
  • CMMB Nasdaq
  • DFLI Nasdaq
  • Market Cap
  • CMMB 13.7M
  • DFLI 14.5M
  • IPO Year
  • CMMB N/A
  • DFLI N/A
  • Fundamental
  • Price
  • CMMB $2.58
  • DFLI $0.89
  • Analyst Decision
  • CMMB Strong Buy
  • DFLI Strong Buy
  • Analyst Count
  • CMMB 2
  • DFLI 1
  • Target Price
  • CMMB $26.50
  • DFLI $1.50
  • AVG Volume (30 Days)
  • CMMB 151.5K
  • DFLI 33.3M
  • Earning Date
  • CMMB 11-12-2025
  • DFLI 11-14-2025
  • Dividend Yield
  • CMMB N/A
  • DFLI N/A
  • EPS Growth
  • CMMB N/A
  • DFLI N/A
  • EPS
  • CMMB N/A
  • DFLI N/A
  • Revenue
  • CMMB N/A
  • DFLI $54,536,000.00
  • Revenue This Year
  • CMMB N/A
  • DFLI $27.77
  • Revenue Next Year
  • CMMB N/A
  • DFLI $42.02
  • P/E Ratio
  • CMMB N/A
  • DFLI N/A
  • Revenue Growth
  • CMMB N/A
  • DFLI 4.80
  • 52 Week Low
  • CMMB $2.39
  • DFLI $0.15
  • 52 Week High
  • CMMB $9.84
  • DFLI $4.99
  • Technical
  • Relative Strength Index (RSI)
  • CMMB 38.12
  • DFLI 44.45
  • Support Level
  • CMMB $2.95
  • DFLI $1.04
  • Resistance Level
  • CMMB $2.80
  • DFLI $1.12
  • Average True Range (ATR)
  • CMMB 0.26
  • DFLI 0.16
  • MACD
  • CMMB -0.09
  • DFLI -0.06
  • Stochastic Oscillator
  • CMMB 2.30
  • DFLI 11.22

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

About DFLI Dragonfly Energy Holdings Corp. (NV)

Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.

Share on Social Networks: